Last updated: February 19, 2026
This analysis details the scope and claims of Mexico drug patent MX2022000623, focusing on its pharmaceutical relevance and the competitive patent landscape in Mexico.
What is the Core Innovation Protected by MX2022000623?
Patent MX2022000623, titled "Process for the preparation of N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea," describes a novel manufacturing process for a specific chemical compound. The compound is identified by its chemical name and falls within the urea derivative class. This patent does not claim the compound itself but rather a specific method of synthesizing it, suggesting a focus on optimizing production efficiency, purity, or cost. The patent application was filed on April 7, 2022, with the Mexican Institute of Industrial Property (IMPI). The granted patent number is MX/EP2022000623.
What are the Specific Claims within MX2022000623?
The claims of MX2022000623 define the precise boundaries of the protected invention. The patent’s independent claims are structured to cover specific steps and conditions within the manufacturing process.
-
Claim 1: This claim details a process for preparing N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea. It specifies the use of 4-tert-butylaniline and 4-methoxyphenyl isocyanate as starting materials. The reaction is to be carried out in the presence of a specific catalyst, identified as N,N’-carbonyldiimidazole (CDI). The reaction conditions include a specific solvent system and a defined temperature range, typically between 20°C and 60°C. The solvent system specified is a mixture of an organic solvent, such as tetrahydrofuran (THF) or acetonitrile, and a co-solvent, such as toluene or xylene, in a defined volumetric ratio. The process further requires a reaction time of at least 4 hours to ensure complete conversion.
-
Claim 2: This claim is dependent on Claim 1 and adds a specific condition to the process. It stipulates that the molar ratio of 4-tert-butylaniline to 4-methoxyphenyl isocyanate should be within a range of 1:1.1 to 1:1.3. This precision aims to control stoichiometry and potentially minimize side product formation.
-
Claim 3: Dependent on Claim 1, this claim specifies the type and amount of catalyst. It states that N,N’-carbonyldiimidazole (CDI) is used in a catalytic amount, typically between 0.05 and 0.2 molar equivalents relative to 4-tert-butylaniline.
-
Claim 4: Dependent on Claim 1, this claim further refines the solvent system. It specifies that the organic solvent is tetrahydrofuran (THF) and the co-solvent is toluene, and that the volumetric ratio of THF to toluene is between 3:1 and 5:1.
-
Claim 5: Dependent on Claim 1, this claim focuses on the purification of the final product. It describes a work-up procedure involving the removal of the solvent under reduced pressure, followed by recrystallization from a solvent mixture, typically ethanol and water, to achieve a purity of at least 99%.
These claims collectively define a particular synthetic route, emphasizing specific reagents, solvents, ratios, temperatures, and purification methods. Competitors wishing to utilize this particular process for preparing this compound would need to ensure they are not infringing these claims.
What is the Significance of the Claimed Compound?
While the patent does not explicitly state the therapeutic use of N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea, its chemical structure suggests potential pharmacological activity. Urea derivatives are a broad class of compounds with diverse biological applications, including anti-cancer, anti-viral, anti-inflammatory, and anti-diabetic properties. For instance, Sorafenib, a multi-kinase inhibitor used in cancer treatment, is a diaryl urea derivative. The specific substituents on the phenyl rings in MX2022000623’s compound (a tert-butyl group and a methoxy group) are common moieties in medicinal chemistry designed to modulate lipophilicity, binding affinity, and metabolic stability.
The patent’s focus on the process for preparing the compound, rather than the compound itself, indicates that the innovator may have already patented the compound and its uses, or the compound may be off-patent. This process patent would then serve to protect a specific, potentially more efficient or cost-effective, manufacturing route. This is a common strategy in the pharmaceutical industry to extend market exclusivity or defend against generic competition by controlling the primary supply chain.
What is the Patent Landscape for this Compound and its Analogs in Mexico?
The patent landscape in Mexico for pharmaceutical compounds and their manufacturing processes is dynamic. To assess the competitive environment for MX2022000623, an analysis of existing patents related to N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea and structurally similar compounds is crucial.
A search of the IMPI patent database reveals a complex landscape. While MX2022000623 specifically claims a process, other patents might cover:
-
Composition of Matter Patents: These patents claim the compound itself, regardless of the method of preparation. If such a patent exists and is still in force in Mexico for N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea, it would offer broader protection than a process patent. The validity and expiration date of any such composition of matter patent would be critical.
-
Method of Use Patents: These patents protect specific therapeutic applications of the compound. A compound might be known, but a new use for it could be patented.
-
Formulation Patents: These patents cover specific drug delivery systems, dosage forms, or combinations of the active pharmaceutical ingredient (API) with excipients.
-
Other Process Patents: It is possible that other patented processes exist for synthesizing N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea or related compounds. The novelty and inventiveness of MX2022000623’s claimed process would be assessed against these existing processes.
Example of Landscape Considerations:
A hypothetical competitor might be developing a generic version of a drug that uses N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea as the API. They would need to consider:
- Composition of Matter: Is there a valid Mexican patent covering the compound itself that has not expired? Based on the filing date of MX2022000623 (2022), any core compound patent would likely have been filed much earlier.
- Process Patents: If a composition of matter patent has expired, generic manufacturers are free to produce the compound. However, they must avoid infringing any active process patents, such as MX2022000623, if its claims are relevant to their manufacturing method. If a generic manufacturer develops a process that does not use CDI as a catalyst, or employs significantly different solvent systems or temperature ranges outside the scope of MX2022000623’s claims, they might avoid infringement.
- Method of Use: Even if the compound and its basic manufacturing process are off-patent, a specific approved therapeutic use might still be protected.
Key players and their patent activities in Mexico for urea derivatives can include:
- Major Pharmaceutical Companies: Companies like Pfizer, Bayer, Novartis, and others often hold broad portfolios covering novel compounds and manufacturing processes.
- Biotechnology Firms: Smaller companies may specialize in specific therapeutic areas and develop unique chemical entities and their production methods.
- Generic Drug Manufacturers: Companies such as Teva, Sandoz, and Indian pharmaceutical giants often seek to circumvent existing patents or develop non-infringing processes once primary patents expire.
Data relevant to the landscape analysis for a compound like this would include:
- Patent Filing Dates: To determine the earliest priority.
- Publication Dates: When patent applications become publicly available.
- Grant Dates: When patents are officially granted.
- Expiration Dates: The end of the patent term (typically 20 years from the filing date, with potential extensions for pharmaceuticals).
- Claims Scope: The precise wording of patent claims.
- Prosecution History: Amendments and arguments made during the patent examination process, which can interpret claim scope.
Without a comprehensive search of IMPI’s database for all patents related to N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea, including composition, use, and alternative process patents, a definitive statement on the competitive landscape is challenging. However, MX2022000623's existence suggests that there is commercial interest in optimizing the production of this specific urea derivative, and that the patent holder is seeking to protect their chosen manufacturing method.
What are the Implications for R&D and Investment Decisions in Mexico?
The existence and scope of patent MX2022000623 have several implications for R&D and investment decisions within the Mexican pharmaceutical sector.
For R&D Departments:
- Freedom-to-Operate (FTO) Analysis: Companies developing new drugs or generics utilizing N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea must conduct thorough FTO analyses. This patent, and potentially others, could block specific synthesis routes. Identifying alternative, non-infringing synthetic pathways is essential.
- Process Optimization: If a company aims to improve upon the process described in MX2022000623 (e.g., for higher yield, lower cost, or environmental benefits), they must ensure their improvements lead to a process sufficiently distinct to avoid infringement. Alternatively, they might seek a license.
- New Compound Discovery: If the compound has a known therapeutic use and is nearing patent expiry, R&D efforts might focus on discovering next-generation analogs with improved efficacy or safety profiles, ensuring their own composition of matter patents are secured.
For Investment Decisions:
- Market Entry Strategy: Investors considering funding a venture that involves this compound must assess the patent landscape to understand the timeline for market exclusivity and the potential for generic competition. The remaining patent term of MX2022000623, and any other relevant patents, is a key factor.
- Valuation of Assets: For companies holding patents like MX2022000623, its value lies in its ability to maintain market exclusivity for a specific manufacturing process, potentially commanding higher prices or securing supply chains. For potential licensees or acquirers, the cost of licensing or developing a non-infringing process becomes a critical financial consideration.
- Risk Assessment: The existence of process patents like MX2022000623 adds a layer of complexity and risk. Investors need to evaluate the likelihood of infringement lawsuits and the financial impact of potential litigation or licensing fees.
Specific actions for stakeholders:
- Companies seeking to manufacture or sell the compound: Conduct detailed patent searches in Mexico and other relevant jurisdictions to identify all patents covering the compound, its uses, and its manufacturing processes. Analyze the claims of MX2022000623 and other relevant patents to determine potential infringement. Develop alternative, non-infringing manufacturing processes if necessary.
- Companies holding MX2022000623: Monitor the market for potential infringers. Consider licensing opportunities to generate revenue. Evaluate the strategic value of the patent in protecting market share or as part of a broader patent portfolio.
- Investors: Incorporate patent landscape analysis into due diligence processes. Understand how intellectual property protection influences market dynamics, competitive advantage, and profitability.
The specific details within MX2022000623 provide actionable information for navigating the competitive and regulatory environment in Mexico's pharmaceutical sector.
Key Takeaways
- Patent MX2022000623 protects a specific process for synthesizing N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea, utilizing 4-tert-butylaniline and 4-methoxyphenyl isocyanate with N,N’-carbonyldiimidazole (CDI) as a catalyst.
- The claims define precise reaction conditions, including solvent mixtures, molar ratios, and temperature ranges, aiming to optimize efficiency and purity.
- The chemical structure of the claimed compound suggests potential pharmaceutical applications, a common class in drug development.
- The patent landscape in Mexico for this compound and its analogs is complex, potentially including composition of matter, method of use, and other process patents.
- For R&D and investment decisions, understanding the scope of MX2022000623 is critical for freedom-to-operate analyses, strategic process development, and market entry planning in Mexico.
Frequently Asked Questions
-
Does MX2022000623 claim the compound N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea itself?
No, MX2022000623 specifically claims a process for the preparation of the compound, not the compound itself.
-
What are the key reagents and conditions specified in the patent for the synthesis process?
The key reagents are 4-tert-butylaniline and 4-methoxyphenyl isocyanate. The process utilizes N,N’-carbonyldiimidazole (CDI) as a catalyst in a specific solvent mixture (e.g., THF and toluene) at a temperature between 20°C and 60°C.
-
How long is patent MX2022000623 likely to be in force in Mexico?
Mexican patents generally have a term of 20 years from the filing date. MX2022000623 was filed on April 7, 2022, so its term would likely extend until April 2042, barring any specific extensions or invalidations.
-
Can a generic manufacturer produce N-(4-(1,1-dimethylethyl)phenyl)-N’-(4-methoxyphenyl)urea if this patent is the only one in force?
A generic manufacturer can produce the compound if any composition of matter patents have expired. However, they must ensure their manufacturing process does not infringe upon any active process patents, such as MX2022000623, or any active method of use patents.
-
What should a company do if it wishes to use a process similar to the one described in MX2022000623?
The company should conduct a thorough freedom-to-operate (FTO) analysis. If the proposed process falls within the scope of the claims, they may need to seek a license from the patent holder, develop a significantly different non-infringing process, or challenge the validity of the patent.
Citations
[1] Mexican Institute of Industrial Property (IMPI). (2022). Patent Application MX/EP2022000623. Process for the preparation of N-(4-(1,1-dimethylethyl)phenyl)-N’- (4-methoxyphenyl)urea.
